SCHEMBL810297

SCHEMBL810297

O=C(Nc1cccc(Nc2ncnc3ncccc23)c1)c1ccccc1Cl

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 1/20 0.55
F2R P25116 1/20 0.53
KDR P35968 1/20 0.52
KCNK3 O14649 2/20 0.52
KCNK9 Q9NPC2 2/20 0.52
ABCG2 Q9UNQ0 2/20 0.52
MAPT P10636 2/20 0.52
KDM4E B2RXH2 1/20 0.52
MEN1 O00255 1/20 0.52
LMNA P02545 1/20 0.52
POLB P06746 1/20 0.52
HPGD P15428 1/20 0.52
STAT3 P40763 1/20 0.52
HTT P42858 1/20 0.52
KMT2A Q03164 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
GRM4 Q14833 2/20 0.51
PABPC1 P11940 1/20 0.50
EIF4H Q15056 1/20 0.50
CYP11B2 P19099 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL810512 0.87 EGFR (0.61) EGFRF2RABCG2MAPTMEN1
SCHEMBL810663 0.85 KCNK3 (0.60) EGFRKDRKCNK3KCNK9MAPT
SCHEMBL1454765 0.84 EGFR (0.56) EGFRKDRKCNK3KCNK9ABCG2
SCHEMBL1455795 0.83 KDR (0.62) EGFRKDRKCNK3KCNK9ABCG2
SCHEMBL811530 0.80 EGFR (0.65) EGFRKDRABCG2KDM4EMEN1
SCHEMBL1455942 0.79 EGFR (0.71) EGFRKDRABCG2MAPTKDM4E
SCHEMBL810220 0.79 AURKB (0.56) EGFRKDRKCNK3KCNK9ABCG2
SCHEMBL1455842 0.77 AURKB (0.58) EGFRKCNK3KCNK9ABCG2MAPT
SCHEMBL809840 0.76 EGFR (0.71) EGFRABCG2MAPTKDM4EMEN1
SCHEMBL810676 0.76 ABCG2 (0.59) EGFRKDRKCNK3KCNK9ABCG2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1971611-B1 ANTI-VIRAL COMPOUNDS ABBOTT LAB (US) 2012-10-10 EP disclosed
EP-1979348-B1 ANTI-VIRAL COMPOUNDS ABBOTT LAB (US) 2012-01-18 EP disclosed
EP-2345652-A1 Antiviral compounds Abbott Laboratories (US) 2011-07-20 EP disclosed
US-7915411-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2011-03-29 US disclosed
US-7910595-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2011-03-22 US disclosed
EP-1979348-A2 ANTI-VIRAL COMPOUNDS Abbott Laboratories (US) 2008-10-15 EP disclosed
EP-1971611-A1 ANTI-VIRAL COMPOUNDS Abbott Laboratories (US) 2008-09-24 EP disclosed
US-20070232627-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. 2007-10-04 US disclosed
US-20070197558-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. 2007-08-23 US disclosed
WO-2007081517-A2 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2007-07-19 WO disclosed
WO-2007076034-A2 ANTI-VIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2007-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197558-A1 ANTI-VIRAL COMPOUNDS HAVCR2, MAVS, EIF2AK2 EGFR 2701/4885F2R 3269/4885KDR 3293/4885
US-20070232627-A1 ANTI-VIRAL COMPOUNDS HAVCR2, MAVS, EIF2AK2 EGFR 2701/4885F2R 3269/4885KDR 3293/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.